CA 19-9 Pancreatic Cancer Marker

• Test Name: CA 19-9 Pancreatic Cancer Marker Test
• Test Type: Blood-based tumour marker test
• Specimen Required: Blood sample (serum)
• Methodology: Enzyme immunoassay (EIA), chemiluminescent immunoassay (CLIA), or similar immunoassay techniques
• Purpose: Measures the level of CA 19-9, a carbohydrate antigen, in the blood, which is often elevated in pancreatic cancer and other malignancies.

• Cancer Detection: Assists in detecting pancreatic cancer and other gastrointestinal malignancies by measuring CA 19-9 levels.
• Monitoring Treatment Response: Evaluates the effectiveness of treatment in patients with pancreatic cancer by tracking changes in CA 19-9 levels over time.
• Prognosis: Helps in assessing the prognosis of patients with pancreatic cancer, where higher levels may indicate more advanced disease.
• Recurrence Monitoring: Used to monitor for recurrence of pancreatic cancer after treatment by regularly measuring CA 19-9 levels.

• Components:
  • Collection of a blood sample from the patient.
  • Measurement of CA 19-9 levels in the serum using a specific immunoassay method.
  • Calibration with standard controls to ensure the accuracy and precision of the results.
  • Reporting of CA 19-9 levels in units per millilitre (U/mL)
     
• Procedure:
  • A blood sample is drawn from the patient.
  • The serum is separated and analyzed for CA 19-9 concentration.
  • Results are compared to established reference ranges to determine if the levels are elevated.

• Normal Findings: Low levels of CA 19-9, typically below 37 U/mL, are considered normal and unlikely to be associated with pancreatic cancer.
• Elevated CA 19-9 Levels: Levels above the normal range may indicate the presence of pancreatic cancer, cholangiocarcinoma, or other gastrointestinal cancers, but can also be elevated in benign conditions like pancreatitis or liver disease.
• Clinical Correlation: CA 19-9 levels should be interpreted in conjunction with imaging studies, clinical symptoms, and other diagnostic tests to accurately diagnose or monitor pancreatic cancer.

• Quantitative: Provides a quantitative measurement of CA 19-9 levels in the blood.
• Interpretation: Results are interpreted based on the reference range, typically with levels above 37 U/mL considered elevated and potentially indicative of malignancy.
• Report: A detailed report includes the measured CA 19-9 level, the reference range, and its clinical significance.
• Turnaround Time: Typically 1-2 days, depending on the laboratory.

Q. What is the CA 19-9 Pancreatic Cancer Marker Test?
The CA 19-9 test measures the level of the CA 19-9 antigen in the blood, which is often elevated in pancreatic cancer and other gastrointestinal cancers
 

Q. Why is the CA 19-9 Test important for pancreatic cancer?
It helps detect pancreatic cancer, monitor treatment response, assess prognosis, and check for recurrence after treatment
 

Q. How is the CA 19-9 Test performed?
A blood sample is drawn from the patient and analyzed in the laboratory to measure CA 19-9 levels using immunoassay techniques
 

Q. What do elevated CA 19-9 levels indicate?
Elevated levels may indicate pancreatic cancer or other gastrointestinal cancers, but can also be elevated in benign conditions like pancreatitis or liver disease
 

Q. Can the CA 19-9 Test diagnose pancreatic cancer on its own?
No, elevated CA 19-9 levels alone are not enough for diagnosis; they should be used alongside imaging studies and other diagnostic tests
 

Q. When should the CA 19-9 Test be repeated?
The test may be repeated regularly during and after treatment for pancreatic cancer to monitor response and check for recurrence
 

Q. How long does it take to get results from the CA 19-9 Test?
Results are usually available within 1-2 days after the blood sample is processed in the laboratory